Immune checkpoint inhibitor–induced myocarditis, myositis, and myasthenia crisis overlap syndrome and mortality: a pooled case analysis

Background Cancer patients on immune checkpoint inhibitors (ICIs) can rarely develop concurrent myocarditis, myositis, and myasthenia gravis, known as 3M syndrome. While a few reviews have been published to better understand the characteristics of 3M patients, no study to date has identified predictors of mortality in these patients.Methods We systematically reviewed five databases for published cases of 3M syndrome from 2014 to 2024. Of 113 articles, we identified 153 adult 3M patients. For each patient, we recorded demographic data, ICI regimen, symptoms, diagnostic findings, treatment modalities, and discharge outcomes. Using multivariable logistic regression, we compared variables by mortality.Results Patients had a median age of 72 years, were predominantly male (73%), and were diagnosed with melanoma (32%). Pembrolizumab (30%) was the most common ICI. Common symptoms were dyspnea (59%), muscle weakness (59%), and dysphagia (37%), and most (73%) had varying degree ocular involvement. Troponin and creatinine kinase were elevated in nearly all patients. We identified three characteristics related to mortality: older age (P = 0.005), elevated liver enzymes (P = 0.02), and intubation (P = 0.002). We also identified factors related to survival: treatment with rituximab (P = 0.04) or abatacept (P = 0.02), elevated lactate dehydrogenase (P = 0.03), and tracheostomy (P = 0.046).Conclusion Further investigation into potential predictors of survival in 3M syndrome patients, particularly regarding rituximab and abatacept use, may improve patient care and outcomes.

Authors

Institutions

Publication Details

Journal
Baylor University Medical Center Proceedings
Published
2026-11-18
DOI
https://doi.org/10.1080/08998280.2026.2757502
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune checkpoint inhibitor–induced myocarditis, myositis, and myasthenia crisis overlap syndrome and mortality: a pooled case analysis

Mohamed Abdul Kader Jailani N, Hossam Albeyoumi Mohammed, Jessica M. Macintyre, Shea‐Lee Godin et al.
4 links
Baylor University Medical Center Proceedings
Cancer Immunotherapy and Biomarkers
article

Immune checkpoint inhibitor–induced myocarditis, myositis, and myasthenia crisis overlap syndrome and mortality: a pooled case analysis

Mohamed Abdul Kader Jailani N, Hossam Albeyoumi Mohammed, Jessica M. Macintyre, Shea‐Lee Godin, Shane J. Sacco, Kerry Shastri Singh, Mira Hasan, Madhumita Kolluri, Christian Tallo, Mirghani F. Mohamed
article en

Abstract

Background Cancer patients on immune checkpoint inhibitors (ICIs) can rarely develop concurrent myocarditis, myositis, and myasthenia gravis, known as 3M syndrome. While a few reviews have been published to better understand the characteristics of 3M patients, no study to date has identified predictors of mortality in these patients.Methods We systematically reviewed five databases for published cases of 3M syndrome from 2014 to 2024. Of 113 articles, we identified 153 adult 3M patients. For each patient, we recorded demographic data, ICI regimen, symptoms, diagnostic findings, treatment modalities, and discharge outcomes. Using multivariable logistic regression, we compared variables by mortality.Results Patients had a median age of 72 years, were predominantly male (73%), and were diagnosed with melanoma (32%). Pembrolizumab (30%) was the most common ICI. Common symptoms were dyspnea (59%), muscle weakness (59%), and dysphagia (37%), and most (73%) had varying degree ocular involvement. Troponin and creatinine kinase were elevated in nearly all patients. We identified three characteristics related to mortality: older age (P = 0.005), elevated liver enzymes (P = 0.02), and intubation (P = 0.002). We also identified factors related to survival: treatment with rituximab (P = 0.04) or abatacept (P = 0.02), elevated lactate dehydrogenase (P = 0.03), and tracheostomy (P = 0.046).Conclusion Further investigation into potential predictors of survival in 3M syndrome patients, particularly regarding rituximab and abatacept use, may improve patient care and outcomes.

Baylor University Medical Center Proceedings
University of Connecticut (US), UConn Health (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon